In the last 10 years, MAP kinase pathway–targeted therapies (BRAF and MEK inhibitors) and immune checkpoint inhibitors blocking CTLA-4 and PD-1 have revolutionized the management of advanced melanoma and significantly prolonged patient survival [149, 151] (Table 2). This evidence concerns the gene MAP2K7 and melanoma.